Direct oral anticoagulants and warfarin for venous thromboembolism treatment: Trends from 2012 to 2017
Open Access
- 9 June 2019
- journal article
- research article
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 3 (4) , 668-673
Abstract
No abstract availableKeywords
Funding Information
- National Heart, Lung, and Blood Institute (R01‐HL131579, R01‐HL122200)
This publication has 14 references indexed in Scilit:
- Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism: a retrospective population-based cohort analysisThe Lancet Haematology, 2019
- Temporal trends in initiation of VKA, rivaroxaban, apixaban and dabigatran for the treatment of venous thromboembolism - A Danish nationwide cohort studyScientific Reports, 2017
- Antithrombotic Therapy for VTE DiseaseChest, 2016
- Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled AnalysisCirculation, 2014
- Edoxaban versus Warfarin for the Treatment of Symptomatic Venous ThromboembolismNew England Journal of Medicine, 2013
- Clinical Pharmacokinetic and Pharmacodynamic Profile of RivaroxabanClinical Pharmacokinetics, 2013
- Ascertainment of warfarin and aspirin use by medical record review compared with automated pharmacy dataPharmacoepidemiology and Drug Safety, 2010
- Oral Rivaroxaban for Symptomatic Venous ThromboembolismNew England Journal of Medicine, 2010
- Dabigatran versus Warfarin in the Treatment of Acute Venous ThromboembolismNew England Journal of Medicine, 2009
- Coding Algorithms for Defining Comorbidities in ICD-9-CM and ICD-10 Administrative DataMedical Care, 2005